

Communicating genome-enhanced risk for cardiovascular disease - an observational follow-up study

Supplementary Information

Information collected with e-questionnaires.

Data on the participants' smoking habits, family history of coronary heart disease (CHD), marital status, and education were collected at baseline by electronic questionnaires. Persons who indicated that they currently smoke either daily or occasionally were scored as smokers. A positive history of early onset family history of CHD was defined based on whether either the father or the mother of the study participants had suffered from myocardial infarction before age 60. The participants' level of education was classified on a scale from 1 – 3: 1) no professional training, 2) vocational education, 3) college or university degree. In addition, the participants also provided information about whether they previously had been diagnosed with diabetes, angina pectoris or heart failure.

Communication of the personal ASCVD risk directly to the participants.

The personal ASCVD risk estimates were communicated to all study participants with the interactive web-tool KardioKompassi®¹ developed in house. KardioKompassi has been designed to enable patients and doctors to manage and use genome information to predict a person's individual risk for ASCVD, and to support primary ASCVD prevention. The disease risk estimate combines traditional health information (age, sex, familial history of early-onset coronary heart disease, smoking, blood cholesterol, and blood pressure)², with a genetic risk score. The score utilized in the GeneRISK –study is based on 49,000 DNA variations associated with coronary heart disease, and was estimated as the sum of the risk alleles weighted by the logarithms of the odds-ratio estimates taken from the CardiogramPlusC4D meta-analysis summary statistic³.

KardioKompassi estimated and presented the individual's disease risk for ASCVD during the next 10 years in two different ways:

- 1) Traditional risk factors only (age, sex, familial history of early-onset coronary heart disease, smoking, blood cholesterol, and blood pressure)
- 2) The combined effect of traditional and genetic risk factors (49,000 DNA-variants associated with coronary heart disease).

The interactive graphical user interface showed the individual's 10-year risk for coronary heart disease and/or stroke both as an absolute number and in relation to the population risk. The development of the risk as a function of age was also shown in a separate graph. To support intervention the graphical interface allowed the user to explore how changing their risk factors (smoking, blood lipids, and blood pressure) would impact on their disease risk.

KardioKompassi interpreted the ASCVD risk according to the Finnish National Guidelines for prevention of coronary heart disease and/or stroke as follows; $\geq 15\%$ risk was considered very high, 10 - 14.9% risk was considered high, 2 - 9.9% risk was considered average, and a 10-year risk was considered $< 2\%$ low. If either of the two 10-year risk assessment (with or without the polygenic risk score) was $\geq 10\%$, KardioKompassi advised the study participant to see his/her doctor to discuss how the risk could be lowered. KardioKompassi did not suggest any specific intervention, i.e. the decision on initiating medical intervention was made by the physician.

KardioKompassi is owned by the Institute for Molecular Medicine Finland (FIMM), University of Helsinki.

¹. KardioKompassi® (www.kardiokompassi.fi) is owned by the Institute for Molecular Medicine Finland (FIMM), University of Helsinki.

². Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. *Arterioscler Thromb Vasc Biol* 2013;33:2261-6.

³. Abraham G, Havulinna AS, Bhalala OG, et al. Genomic prediction of coronary heart disease. *Eur Heart J* 2016;37:3267-78.

Supplementary Table 1. Analysis of persons attending vs. not attending the follow-up study. Attendance was defined as having completed the follow-up questionnaire.

	Participated in follow-up	Did not participate in follow-up
N	5,191	2,151*
Age (years)	56.2 ± 5.8	54.8 ± 5.6*
N females (%)	3,325 (64.1%)	1,366 (63.5%)
BMI (kg/m ³)	27.0 ± 4.8	28.3 ± 5.2*
BMI ≥ 30 (N (%))	1,085 (20.9%)	704 (32.7%)*
Waist circumference (cm)	93.3 ± 13.5	96.6 ± 14.6*
Total cholesterol (mmol/l)	5.6 ± 1.0	5.6 ± 1.0
HDL-C* (mmol/l)	1.68 ± 0.5	1.60 ± 0.5*
LDL-C* (mmol/l)	3.4 ± 0.9	3.4 ± 0.9
S-triglycerides (mmol/l)	1.2 ± 0.9	1.3 ± 0.9*
ApoA1 (mmol/l)	1.70 ± 0.29	1.67 ± 0.30 [†]
ApoB (mmol/l)	0.99 ± 0.26	1.02 ± 0.28*
Systolic blood pressure (mmHg)	129.0 ± 16.6	130.7 ± 17.1*
Diastolic blood pressure (mmHg)	85.4 ± 10.0	86.7 ± 10.4*
Daily smokers (N (%))	760 (14.6%)	503 (23.4%)*
Using lipid-lowering medication (N (%))	594 (11.4%)	223 (10.4%)*
Using blood pressure-lowering medication (N (%))	1080 (20.8%)	534 (24.8%)*

* p<0.001 vs. participated in follow-up

[†]p<0.003 vs. participated in follow-up

Supplementary Table 2. Baseline characteristics by clinical center.

	Carea		Mehiläinen		VPU	
	Males	Females	Males	Females	Males	Females
N	1916	2941	312	1057	423	693
Age (years)	56.1 ± 5.8	56.0 ± 5.7	56.0 ± 6.0	55.6 ± 5.6	55.1 ± 6.0	54.7 ± 5.7
BMI (kg/m²)	28.0 ± 4.5	27.4 ± 5.5	27.2 ± 4.1	26.8 ± 4.9	26.6 ± 3.7	26.8 ± 4.8
BMI ≥ 30 (N (%))	513 (26.8%)	768 (26.4%)	61 (19.6%)	231 (21.9%)	72 (17.0%)	144 (29.2%)
Waist circumference (cm)	101.5 ± 12.8	91.3 ± 13.9	99.2 ± 11.8	89.5 ± 12.5	97.6 ± 11.2	89.8 ± 12.2
Total cholesterol (mmol/l)	5.5 ± 1.0	5.6 ± 1.0	5.4 ± 1.1	5.6 ± 1.0	5.6 ± 1.0	5.8 ± 1.0
HDL-C* (mmol/l)	1.40 ± 0.44	1.75 ± 0.49	1.46 ± 0.46	1.82 ± 0.50	1.52 ± 0.46	1.90 ± 0.50
LDL-C** (mmol/l)	3.4 ± 0.9	3.3 ± 0.9	3.4 ± 1.0	3.26 ± 0.9	3.5 ± 0.9	3.4 ± 1.0
S-triglycerides (mmol/l)	1.53 ± 1.28	1.16 ± 0.63	1.35 ± 0.72	1.14 ± 0.77	1.41 ± 0.92	1.10 ± 0.51
ApoA1 (mmol/l)	1.57 ± 0.26	1.72 ± 0.29	1.58 ± 0.27	1.77 ± 0.30	1.64 ± 0.26	1.84 ± 0.30
ApoB (mmol/l)	1.07 ± 0.27	0.97 ± 0.26	1.03 ± 0.28	0.96 ± 0.25	1.06 ± 0.26	0.97 ± 0.25
Systolic blood pressure (mmHg)	135.6 ± 15.9	127.9 ± 17.1	134.1 ± 14.6	126.1 ± 15.5	130.8 ± 14.6	121.8 ± 15.8
Diastolic blood pressure (mmHg)	89.3 ± 10.0	84.9 ± 10.1	87.5 ± 9.2	84.3 ± 9.3	84.9 ± 9.4	81.8 ± 9.5
Daily smokers (N (%))	298 (15.6%)	374 (12.7%)	15 (4.8%)	51 (4.8%)	15 (3.5%)	26 (5.3%)
Using lipid-lowering medication (N (%))	291 (15.2%)	311 (10.6%)	51 (16.3%)	97 (9.2%)	38 (9.0%)	29 (5.9%)
Using blood pressure-lowering medication (N (%))	495 (25.8%)	670 (22.8%)	78 (25.0%)	211 (19.9%)	69 (16.3%)	91 (18.5%)

Carea: Kymenlaakso social and health care services in Southeastern Finland; Mehiläinen: Mehiläinen Oy; VPU: Finnish Red Cross Blood Service. Data are presented as mean ±SD unless otherwise indicated.

Supplementary Table 3. Factors associating with the likelihood of viewing one's personal ASCVD-risk results at least once using KardioKompassi*

Explanatory variable	OR	P-value
Sex (male)	0.57 (0.49-0.67)	P < 0.001
Age	0.99 (0.98-1.00)	0.08
Center: Mehilainen †	0.96 (0.78-1.18)	0.7
Center: Blood Service †	2.96 (2.15-4.08)	P < 0.001
Marital status	1.27 (1.07-1.51)	0.0077
Education (per additional level)	1.37 (1.20-1.57)	P < 0.001

* 6,586 individuals viewed their results at least once, whereas 736 participants did not access their results at all.

† Carea as reference

Carea: Kymenlaakso social and health care services in Southeastern Finland; Mehiläinen: Mehiläinen Oy; VPU: Finnish Red Cross Blood Service.

Supplementary Table 4. Overlap between individuals at high ($\geq 10\%$) 10-year risk for ASCVD who saw his/her doctor and persons who had weight loss

	WEIGHT LOSS: NO	WEIGHT LOSS: YES	TOTAL
SAW DOCTOR: NO	482 (70,6 %)	59 (8,6 %)	541 (79,2 %)
SAW DOCTOR: YES	116 (17,0 %)	26 (3,8 %)	142 (20,8 %)
TOTAL	598 (87,6 %)	85 (12,4 %)	683 (100 %)

Supplementary Table 5. Multivariate analyses* of factors associated with reporting that the personal ASCVD-result was concerning.

Response variable: I received concerning risk results

Explanatory variable	OR (CI)	P
Age (yrs)	0·983 (0·968-0·999)	3·47E-02
Sex (female)	0·504 (0·426-0·596)	1·40E-15
Education (per additional level)	1·978 (1·298-3·014)	1·51E-03
Clinical ASCVD risk (SD)	1·198 (1·074-1·337)	1·24E-03
PRS (SD)	1·539 (1·377-1·721)	3·34E-14

ASCVD = atherosclerotic cardiovascular disease; PRS = polygenic risk score

Level of education was classified on a scale from 1 – 3: 1) no professional training, 2) vocational education, 3) college or university degree

* Adjusted for clinical center.